Publications en collaboration avec des chercheurs de University of Manchester (8)

2023

  1. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours

    European Journal of Cancer, Vol. 188, pp. 39-48

2020

  1. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

    European Urology

  2. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees

    European Urology, Vol. 77, Núm. 2, pp. 223-250

2019

  1. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

    Annals of Oncology, Vol. 30, Núm. 11, pp. 1697-1727

2017

  1. Sunitinib in pancreatic neuroendocrine tumors: Updated progression-free survival and final overall survival from a phase III randomized study

    Annals of Oncology, Vol. 28, Núm. 2, pp. 339-343

2016

  1. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1660-1668

2014

  1. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

    International Journal of Oncology, Vol. 44, Núm. 1, pp. 5-16

  2. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: A medical chart review across ten centers in five European countries

    Cancer Medicine, Vol. 3, Núm. 6, pp. 1517-1526